Drug Profile
Ferric bepectate - Iron4U
Alternative Names: Feramyl; Ferric hydroxide hydroxyethyl starch glucoheptonic acid complex; Iron (III) hydroxide hydroxyethyl starch glucoheptonic acid complex; Iron HES complex - SerumWerk Bernburg; Iron-(III)-hydroxyethyl-starch; Iron-hetastarch complex - SerumWerk Bernburg; PolyglucoferronLatest Information Update: 07 Sep 2022
Price :
$50
*
At a glance
- Originator Serumwerk Bernburg
- Developer iron4u; Serumwerk Bernburg
- Class Antianaemics; Heavy metals; Iron compounds
- Mechanism of Action Iron replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Iron deficiency anaemia
Most Recent Events
- 07 Sep 2022 Ferric bepectate is still in phase III trials for Iron deficiency anemia in Germany (iron4U pipeline, September 2022)
- 11 Mar 2020 Iron4U suspended the phase-III trial due to difficult recruitment and wanted to redesign in Iron deficiency anaemia in Germany (IV) (NCT04087993)
- 19 Sep 2019 Phase III development is ongoing in Germany